comparemela.com

Page 2 - Dyne Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dyne Therapeutics Duchenne muscular dystrophy treatment shows promise

Dyne released promising new data on its Duchenne muscular dystrophy drug, DYNE-251, as well as its myotonic dystrophy type 1 treatment DYNE-101.

Wildon farwellJoshua brummDyne therapeuticSarepta therapeuticDrug administration

Reviewing Dyne Therapeutics (NASDAQ:DYN) & Capstone Therapeutics (OTCMKTS:CAPS)

Capstone Therapeutics (OTCMKTS:CAPS – Get Rating) and Dyne Therapeutics (NASDAQ:DYN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability. Risk and Volatility Capstone Therapeutics has a beta of […]

United statesCapstone therapeutics corpDyne therapeutics incCapstone therapeuticsGet ratingDyne therapeuticsGiven dyne therapeuticDyne therapeuticCapstone therapeutics dailyOtcmkts capsStock comparisonStock analysis

FDA Grants Fast Track Designation to Dyne s Treatment for Duchenne Muscular Dystrophy

FDA Grants Fast Track Designation to Dyne s Treatment for Duchenne Muscular Dystrophy
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesWildon farwellDrug administrationFast trackDyne therapeuticAccelerated approvalPriority review

Analysts Anticipate Dyne Therapeutics, Inc (NYSE:DYN) to Announce -$0 81 Earnings Per Share

Brokerages expect Dyne Therapeutics, Inc. (NYSE:DYN – Get Rating) to report earnings per share (EPS) of ($0.81) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Dyne Therapeutics’ earnings, with estimates ranging from ($0.88) to ($0.70). Dyne Therapeutics posted earnings per share of ($0.58) during the same quarter last year, which […]

United statesZacks investment researchDyne therapeutics incDyne therapeutics company profile get ratingDyne therapeuticsGet ratingDyne therapeuticTherapeutics company profileNyse dyn

-$0 88 Earnings Per Share Expected for Dyne Therapeutics, Inc (NYSE:DYN) This Quarter

Brokerages expect Dyne Therapeutics, Inc. (NYSE:DYN – Get Rating) to post earnings per share (EPS) of ($0.88) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Dyne Therapeutics’ earnings. The lowest EPS estimate is ($1.06) and the highest is ($0.74). Dyne Therapeutics reported earnings per share of ($0.50) during […]

United statesZacks investment researchDyne therapeutics incDyne therapeuticsGet ratingDyne therapeuticNyse dyn

vimarsana © 2020. All Rights Reserved.